Dexcom SEC filings, summarized

Dexcom Promotes CFO Jereme Sylvain to Chief Operating Officer

On September 14, 2026, Dexcom promoted Executive Vice President and CFO Jereme Sylvain to COO while retaining his finance responsibilities. Sylvain will…

Dexcom Promotes CFO Jereme Sylvain to Chief Operating Officer

Dexcom appointed Executive Vice President and Chief Financial Officer Jereme Sylvain as Chief Operating Officer effective September 14, 2026, adding…

Dexcom appoints former Stryker CFO Glenn Boehnlein to its board

Dexcom appointed Glenn Boehnlein to its Board of Directors effective September 10, 2026. Boehnlein served as Stryker’s vice president and CFO from 2016 to…

Dexcom appoints former Stryker CFO Glenn Boehnlein to its board

Dexcom appointed Glenn Boehnlein as an independent director effective September 10, 2026, expanding its board to 13 members and adding him to the Operations…

Dexcom Executive Chair Kevin Sayer sells $2.4M in stock

Kevin Sayer, Dexcom’s executive chair and a director, sold 26,756 shares in three open-market transactions on August 20, 2026. He sold 19,308 shares at…

DexCom reports 13% revenue growth and raises 2026 margin guidance

DexCom’s second-quarter 2026 revenue rose 13% year over year to $1.308 billion, while GAAP net income increased to $249.1 million, or $0.64 per diluted…

Dexcom Executive Chair Kevin Sayer sells $2.0M in stock

Kevin Sayer, Dexcom’s executive chair and a director, sold 26,756 shares of common stock on July 20 at $76.32 per share, for approximately $2.04 million. He…

DexCom files 8-K (Item 9.01): Exhibit 10.1 — Letter Agreement dated Feb 27, 2026 between DexCom, Inc.

DexCom files 8-K (Item 9.01): Exhibit 10.1 — Letter Agreement dated Feb 27, 2026 between DexCom, Inc. and Kevin Sayer; noted as a management/compensatory…

Kevin R.

Kevin R. Sayer returned from a temporary leave and resumed his role as Executive Chairman of DexCom effective Mar 2, 2026 (he retired as CEO on Jan 1,…

Dexcom filed Form 8‑K on Feb 26, 2026: Item 9.01 lists Exhibit 99.1 (press release dated Feb 26, 2026) and…

Dexcom filed Form 8‑K on Feb 26, 2026: Item 9.01 lists Exhibit 99.1 (press release dated Feb 26, 2026) and Exhibit 104 (Inline XBRL cover page). Report…

Dexcom ($DXCM) announced on Feb 26, 2026 the appointment of Mr.

Dexcom ($DXCM) announced on Feb 26, 2026 the appointment of Mr. Osterloh to its Board. Press release furnished as Exhibit 99.1 to the 8‑K and incorporated…

Dexcom Board expands to 12; appointed Albert F.

Dexcom Board expands to 12; appointed Albert F. “Rick” Osterloh IV as director effective Feb 26, 2026. Term expires at the 2026 annual meeting. He joins the…

Dexcom filed an 8‑K (Item 9.01) on Feb 12, 2026 — exhibits: Press Release (Ex.

Dexcom filed an 8‑K (Item 9.01) on Feb 12, 2026 — exhibits: Press Release (Ex. 99.1) and Inline XBRL Cover Page (Ex. 104). Filing signed by EVP & CFO Jereme…

Dexcom ($DXCM) issued a press release on Feb 12, 2026 announcing financial results for Q4 and FY ended Dec…

Dexcom ($DXCM) issued a press release on Feb 12, 2026 announcing financial results for Q4 and FY ended Dec 31, 2025; release furnished as Exhibit 99.1 —…

DEXCOM filed an 8‑K on Jan 12, 2026 furnishing exhibits: press releases dated Jan 12, 2026 (Ex.99.1) and…

DEXCOM filed an 8‑K on Jan 12, 2026 furnishing exhibits: press releases dated Jan 12, 2026 (Ex.99.1) and Jan 7, 2026 (Ex.99.2), plus Cover Page Inline XBRL…

Dexcom CEO Jake Leach to present at J.P.

Dexcom CEO Jake Leach to present at J.P. Morgan Healthcare Conf on Jan 12, 2026 at 10:30 AM ET — will report preliminary, unaudited Q4 2025 & FY2025 results…

DexCom filed an 8‑K adding an Offer Letter effective Jan 1, 2026 with Jacob S.

DexCom filed an 8‑K adding an Offer Letter effective Jan 1, 2026 with Jacob S. Leach (Ex.10.1 — management/compensatory arrangement). Filing does not…

Dexcom appoints Jacob S.

Dexcom appoints Jacob S. Leach as President & CEO and director effective Jan 1, 2026; he’s been interim CEO during Kevin Sayer’s medical leave. Board…